Journal of pediatric gastroenterology and nutrition
-
J. Pediatr. Gastroenterol. Nutr. · Sep 2003
Recombinant factor VIIa improves coagulopathy caused by liver failure.
Coagulopathy is an important cause of morbidity and mortality in patients with liver failure. The benefit of traditional therapies to correct coagulation is often limited and short-lived. Our aim is to identify indications for rFVIIa use and the outcome of treatment in children with liver failure. ⋯ In patients with liver failure, rFVIIa therapy quickly normalizes the PT and maintains improved hemostasis, even when coagulopathy has been refractory to fresh frozen plasma. Therapy subjectively reduces clinical bleeding and can improve fluid balance, without complications.